Virtual Eye Modeling for Ocular Drug Delivery Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for testing medical treatments for the human eye face limitations due to in vitro and in vivo testing constraints, including availability, cost, and ethical considerations, necessitating a more accurate and efficient approach.
Innovation Solution
A computer-implemented method using a mathematical model that includes a geometry equation for the vitreous body and a set of equations for drug convection, allowing simulations of ocular drug delivery with parameters such as drug type, concentration, amount, injection position, and penetration depth, to optimize treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used to test medical treatments for eye diseases, then treatment efficacy can be evaluated, but the complexity of human eye disease mechanisms cannot be fully captured
Solution Approach 1:
The patent creates a virtual replica of the human eye using imaging data and computational models. This virtual eye model copies the structural and functional characteristics of the human eye, allowing researchers to test treatments in a digital environment that accurately represents human anatomy and pathology, thereby eliminating the limitation of using simplified animal models.
Solution Approach 2:
The patent replaces physical animal models with a computational simulation system. Instead of using biological organisms for testing, the invention uses computer-generated virtual eyes that can be manipulated, observed, and tested through simulations, thereby capturing human-specific eye disease mechanisms that animal models cannot replicate.
2Reliability
If extensive testing on animal models is conducted, then treatment safety can be assessed, but the time required for development is extended
Solution Approach 1:
The patent performs preliminary safety assessments using virtual eye models before conducting actual clinical trials. By simulating treatment effects and potential side effects in advance on virtual replicas of the human eye, researchers can identify safety concerns early, reducing the time needed for subsequent animal testing and clinical trial phases.
Solution Approach 2:
The virtual eye model serves as a preliminary testing platform that replicates human eye anatomy and disease states. This allows safety assessments to be conducted in silico (using computer simulations) before physical testing, thereby accelerating the development timeline while maintaining safety evaluation rigor.
3Loss of information
If traditional imaging techniques are used to capture eye structure, then anatomical information can be obtained, but functional and molecular information is insufficient
Solution Approach 1:
The patent merges multiple imaging modalities (structural, functional, and molecular imaging) into a unified virtual eye model. By combining data from different imaging techniques and sources, the system creates a comprehensive digital representation that includes anatomical structure, functional characteristics, and molecular information, thereby eliminating information gaps without creating overwhelming data volumes.
Solution Approach 2:
The virtual eye model serves multiple functions simultaneously: it stores anatomical information, functional data, and molecular characteristics in a single integrated platform. This multi-functional system allows researchers to access and analyze all types of eye-related information from one source, improving information completeness while managing data quantity through structured organization.
Data Source
Figure 1
Figure 2a~2b
Figure 2c
AI summary
A computer-implemented method for testing ocular drug delivery is provided. The ocular drug delivery is characterized by a set of delivery parameters comprising at least one of drug type, drug concentration, drug amount, injection position, penetration depth. The method comprises: providing a model for the human eye, wherein the model comprises: a geometry equation defining a three-dimensional generalized limacon for the geometry of the vitreous body, geometry equations describing all components of the eye; and a set of equations defining a drug convection in the vitreous body; setting a target drug state in the vitreous body; using the model to perform at least one simulation of the ocular drug delivery with a given set of values for the set of delivery parameters, wherein the at least one simulation provides a simulated drug state in the vitreous body; comparing the target drug state and the simulated drug state.